Navigation Links
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
Date:11/2/2007

uld differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the results of any failure of XL784 to demonstrate safety and efficacy in clinical testing, risks related to Exelixis' arrangement with SEI and Exelixis' dependence on and relationship with GSK. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and Exelixis' other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS ... and Manufacturing Intelligence , today announces Infusion ... The event will be held Oct. 9-10, 2014, ... is designed to showcase the necessity for implementing ... metrics and Manufacturing Intelligence to gain insight into ...
(Date:8/21/2014)... -- Professional Compounding Centers of America (PCCA) will ... three best scientific presentations at the sixth ... Formulating Better Medicines for Children  conference, held ... Greece , includes dozens of poster-style scientific ... three winners will be selected by a panel ...
(Date:8/21/2014)... MENLO PARK, Calif. , Aug. 21, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, announced ... ("Nat") Ricciardi to the Company,s newly expanded Board of ... now comprises eight directors, three of whom are independent. ... years of experience working with emerging growth companies. He ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
(Date:8/21/2014)... College of Chest Physicians (CHEST) announces the immediate ... Injured During Pandemics and Disasters: CHEST Consensus Statement ... journal CHEST while the global health-care ... The consensus statement aims to guide ethical decision-making, ... crises. The statement was developed by over 100 ...
(Date:8/21/2014)... (Aug. 21, 2014) An international scientific collaboration led ... genetic alterations that may contribute to a rare form ... this rare cancer but other types as well. , ... Health,s Cancer Genome Atlas initiative , completed the ... results today in the journal Cancer Cell . ...
(Date:8/21/2014)... Utah scientists have developed a genetically engineered line of ... new research on epilepsy, Alzheimer,s and other diseases. ... in degree of fluorescence in response to different calcium ... called astrocytes and microglia, to be studied in a ... to decipher how the brain works," said Petr ...
(Date:8/21/2014)... The Mount Sinai Hospital has expanded its ... captures real-time patient feedback and enables staff to make ... now available to admitted patients in the Hospital’s cardiology, ... satisfaction using smartphones. , "We are expanding our ... the timely information we need to respond to patient ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Greater awareness ... to have babies before they are full term has ... some areas of the country, early elective deliveries (EEDs) ... last 20 years, EED is defined as delivery before ... linked to neonatal morbidity and mortality, and offers no ...
Breaking Medicine News(10 mins):Health News:CHEST releases new expert guidance in care of the critically ill and injured 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 3Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3
... window of vulnerability for developing binge eating disorder, especially ... study from the University of North Carolina at Chapel ... long-term study of 100,000 pregnant Norwegian women, the researchers ... eating disorder that began during pregnancy. The research is ...
... By furthering scientists understanding of the molecular mechanisms that ... majority of ineffective antibodies, the work may have implications ... The study was published on September 6, 2007, in ... of the effort to understand how protection against HIV ...
... to Peter B. Ajluni, D.O., American Osteopathic,Association (AOA) President, ... of,Americans without health insurance to 47 million --- as ... --- is a disturbing trend signaling,more must be done ... As lawmakers return this week from the summer recess, ...
... Sept. 6 H.E.A.R.T 911 is a,non-profit, non-sectarian ... fighters and construction trade union workers, all of,whom ... 11th attacks and,surviving family members of those who ... nation-wide to situations that arise during,natural or man-made ...
... promotes free quit-smoking services from ClearWay ... ... a,dramatic new billboard will catch the eye of motorists on Interstate ... a,giant ashtray, the billboard will call attention to QUITPLAN(R) Services,Clearway Minnesota,s ...
... Interactive Workshop Features CML Expert, Jorge Cortes, M.D., ... an,expert on leukemia, will discuss novel treatment approaches for ... CML: A,Model in Cancer Therapy. The program is scheduled ... ET. The program is being offered by The ...
Cached Medicine News:Health News:Pregnancy may increase the risk of developing binge eating disorder 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 3Health News:Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911. 2Health News:Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: